Sanofi and Regeneron Pharmaceuticals drug Dupixent has won FDA approval for chronic spontaneous urticaria, introducing a new approach to the treatment of this inflammatory skin disorder. It’s the ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Among other things, we talked about President Trump’s “most-favored nations” policy on drug pricing and why Regeneron is the ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years and above, ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

At the 44 th Annual J.P. Morgan Healthcare Conference, Sanofi’s growth and projection for 2026 up until the end of the decade ...

The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

The patent for Dupixent, called the "miracle atopic dermatitis treatment," will expire around 2031. Dupixent was co-developed by French drugmaker Sanofi and U.S. biotech Regeneron and posted $14.1 ...

Investing.com -- UBS downgraded French pharmaceutical giant Sanofi SA (EPA:SASY) to “neutral” from “buy” rating and cut its ...

A diagnosis of T-cell lymphoma after using Dupixent raises serious questions for patients and families. Many want clear answers about whether they may have a legal claim and what criteria determine ...